The number of gun-related deaths per year in America is now at its highest point in the last 30 years. But in California, in that same time frame, the numbers have fallen by nearly 30 percent—due in no small part to the relentless efforts of Dr. Garen Wintemute.
With those challenges in mind, Len Abbeduto and other leaders at the MIND Institute – known as one of the world’s leading neurodevelopmental research, clinical, educational centers – are launching a new effort to pioneer a first-of-its-kind lifespan approach to autism.
Carlo Sandoval's Make-A-Wish wish was to do something kind for kids with autism, so the UC Davis MIND Institute purchased a VECTA calming station, which will be officially known as “Carlo’s Calming Station.”
Physicians and researchers at the UC Davis Violence Prevention Research Program and several other organizations have developed a clinical guide to help providers get more comfortable recognizing a patient's risk of firearm injury or death.
UC Davis School of Veterinary Medicine was instrumental in the remarkable recovery of this dog after suffering a broken ulna and radius. This is just one example of the unparalleled expertise found at UC Davis.
Scott Fishman, M.D., UC Davis Health director for the Center for Advancing Pain Relief, has seen firsthand the pervasive pain problem plaguing the United States over the past several decades. Fishman’s proposed Big Idea would commission a UC Davis Pain Relief Center, which would serve as a hub for education, research and integrative care –– a groundbreaking resource for clinicians to rethink how to view pain relief and pain management.
In the largest non-pharmacological trial ever in children with fragile X syndrome (FXS), UC Davis researchers found that large-scale, in-home cognitive interventions are feasible and may be beneficial for individuals with the syndrome and potentially other intellectual disabilities.
Leaders of UC Davis Healthannounced Thursday that the state of California has awarded its scientists and clinicians $8.8 million – or almost 42 percent – of a $21 million package earmarked for the study of Alzheimer’s disease.